-
11.发明授权Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism 失效通过确定TAFI-Ile347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US08420321B2
公开(公告)日：2013-04-16
申请号：US13109111
申请日：2011-05-17
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
12.发明授权Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof 失效EDG5多态性V286A与II型糖尿病和静脉血栓形成/肺栓塞的关系及其用途公开(公告)号：US08198022B2
公开(公告)日：2012-06-12
申请号：US13006619
申请日：2011-01-14
申请人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Sylvain Ricard , Sandrine Mace , Jean-Francois Deleuze
发明人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Sylvain Ricard , Sandrine Mace , Jean-Francois Deleuze
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
摘要翻译： 本发明涉及鉴定受试者中II型糖尿病，静脉血栓形成或肺栓塞风险增加的方法，其中286位从缬氨酸（Val）到丙氨酸（Ala）的氨基酸交换的存在 在取自受试者的生物样品中的EDG5蛋白中。
-
13.发明申请ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF 失效EDG5多态性V286A与II型糖尿病和静脉血栓形成/肺动脉栓塞的联合及其使用公开(公告)号：US20110104704A1
公开(公告)日：2011-05-05
申请号：US13006619
申请日：2011-01-14
申请人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
摘要翻译： 本发明涉及鉴定受试者中II型糖尿病，静脉血栓形成或肺栓塞风险增加的方法，其中286位从缬氨酸（Val）到丙氨酸（Ala）的氨基酸交换的存在 在取自受试者的生物样品中的EDG5蛋白中。
-
14.发明授权Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof 失效EDG5多态性V286A与II型糖尿病和静脉血栓形成/肺栓塞的关系及其用途公开(公告)号：US07262273B2
公开(公告)日：2007-08-28
申请号：US10393870
申请日：2003-03-21
申请人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
摘要翻译： 本发明涉及鉴定受试者中II型糖尿病，静脉血栓形成或肺栓塞风险增加的方法，其中286位从缬氨酸（Val）到丙氨酸（Ala）的氨基酸交换的存在 在取自受试者的生物样品中的EDG5蛋白中。
-
15.发明申请Method of Diagnosis of a Predisposition to Develop Thrombotic Disease and Its Uses 失效诊断血栓形成疾病倾向的方法及其应用公开(公告)号：US20080038722A1
公开(公告)日：2008-02-14
申请号：US10592692
申请日：2005-03-16
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.
摘要翻译： 本发明涉及诊断发生血栓形成疾病的倾向，测试系统及其用于诊断倾向于发展血栓形成性疾病的用途的方法，以诊断P 启动子变体及其用于筛选抗血栓形成剂的用途，以及用于鉴定可以用抗血栓形成剂预防性或治疗性治疗的个体的方法，或用于调整治疗或预防剂量的抗血栓形成剂 血栓形成剂。
-
16.发明授权Method of diagnosis of a predisposition to develop thrombotic disease and its uses 失效诊断倾向性发展为血栓性疾病及其用途的方法公开(公告)号：US07785781B2
公开(公告)日：2010-08-31
申请号：US10592692
申请日：2005-03-16
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.
摘要翻译： 本发明涉及诊断P2V1启动子变体及其用于筛选抗血栓形成剂的用于发展血栓形成疾病，测试系统及其用于诊断倾向于发展血栓形成疾病的用途的倾向性的方法 以及用于鉴定可以用抗血栓形成剂预防性或治疗性治疗的个体的方法，或用于调整治疗或预防剂量的抗血栓形成剂。
-
公开(公告)号：US20050003417A1
公开(公告)日：2005-01-06
申请号：US10869977
申请日：2004-06-17
申请人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jesus Benavides , Jean-Francois Deleuze
发明人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jesus Benavides , Jean-Francois Deleuze
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： Methods for the diagnosis or for the prognosis of Alzheimer's disease in an individual. Said method comprises at least one step of detection of the presence or absence of the minor allele of the rs908832 polymorphism of the ABCA2 gene. The presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene indicates that the individual may be suffering from Alzheimer's disease or else exhibits an increased risk of developing Alzheimer's disease.
摘要翻译： 用于个体诊断或预测阿尔茨海默病的方法。 所述方法包括检测ABCA2基因的rs908832多态性的次要等位基因的存在或不存在的至少一个步骤。 ABCA2基因的rs908832多态性的次要等位基因的存在表明个体可能患有阿尔茨海默病，或者表现出发展为阿尔茨海默病的风险增加。
-
公开(公告)号：US07803538B2
公开(公告)日：2010-09-28
申请号：US10869977
申请日：2004-06-17
申请人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jésus Benavides , Jean-François Deleuze
发明人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jésus Benavides , Jean-François Deleuze
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for diagnosing an individual for early onset Alzheimer's disease by measuring the presence or absence of the minor allele of the rs908832 polymorphism of the ABCA2 gene. The presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene indicates that the individual may be suffering from Alzheimer's disease or exhibits an increased risk of developing Alzheimer's disease.
摘要翻译： 本发明涉及通过测定ABCA2基因的rs908832多态性的次要等位基因的存在或不存在来诊断个体的早发性阿尔茨海默病的方法。 ABCA2基因的rs908832多态性的次要等位基因的存在表明该个体可能患有阿尔茨海默氏病或表现出发展为阿尔茨海默氏病的风险增加。
-
公开(公告)号：US08835618B2
公开(公告)日：2014-09-16
申请号：US13209495
申请日：2011-08-15
申请人： Alexis Brice , Christophe Lucking , Patrice Denefle , Sylvain Ricard , Nacer Eddine Abbas , Sandrine Bouley
发明人： Alexis Brice , Christophe Lucking , Patrice Denefle , Sylvain Ricard , Nacer Eddine Abbas , Sandrine Bouley
CPC分类号： C12Q1/6883 , C07K16/40 , C12N9/104 , C12N9/93 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , C12Y603/02019
摘要： The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
摘要翻译： 本发明涉及编码人parkin基因的突变形式或截短形式的核酸或包含外显子增殖的形式，以及相应的蛋白质和抗体。 本发明还涉及用于鉴定parkin基因突变的方法和试剂盒，并用于研究用于治疗目的的化合物。
-
公开(公告)号：US20120064598A1
公开(公告)日：2012-03-15
申请号：US13209495
申请日：2011-08-15
申请人： Alexis Brice , Christophe Lucking , Patrice Denefle , Sylvain Ricard , Nacer Eddine Abbas , Sandrine Bouley
发明人： Alexis Brice , Christophe Lucking , Patrice Denefle , Sylvain Ricard , Nacer Eddine Abbas , Sandrine Bouley
IPC分类号： C12N9/00 , C07K16/40 , C07H21/00 , C12N5/10 , C12N5/04 , C12N1/21 , C12N1/19 , C12N15/52 , C12N15/63
CPC分类号： C12Q1/6883 , C07K16/40 , C12N9/104 , C12N9/93 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , C12Y603/02019
摘要： The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
摘要翻译： 本发明涉及编码人parkin基因的突变形式或截短形式的核酸或包含外显子增殖的形式，以及相应的蛋白质和抗体。 本发明还涉及用于鉴定parkin基因突变的方法和试剂盒，并用于研究用于治疗目的的化合物。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.029 秒)
